Published in J Neuroimmune Pharmacol on September 14, 2012
Cannabinoids as therapeutic agents in cancer: current status and future implications. Oncotarget (2014) 1.05
Neuroprotective properties of cannabigerol in Huntington's disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice. Neurotherapeutics (2015) 0.83
A cannabigerol derivative suppresses immune responses and protects mice from experimental autoimmune encephalomyelitis. PLoS One (2014) 0.78
An update on PPAR activation by cannabinoids. Br J Pharmacol (2016) 0.78
Cannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the Evidence. Front Pharmacol (2016) 0.78
VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington's disease. Sci Rep (2016) 0.76
Molecular Targets of the Phytocannabinoids: A Complex Picture. Prog Chem Org Nat Prod (2017) 0.75
Cannabinoid CB2 receptors are involved in the protection of RAW264.7 macrophages against the oxidative stress: an in vitro study. Eur J Histochem (2017) 0.75
Plastic and Neuroprotective Mechanisms Involved in the Therapeutic Effects of Cannabidiol in Psychiatric Disorders. Front Pharmacol (2017) 0.75
The molecular receptive ranges of human TAS2R bitter taste receptors. Chem Senses (2009) 3.45
Pharmacology of vanilloid transient receptor potential cation channels. Mol Pharmacol (2009) 2.00
Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia (2014) 1.97
The 'headache tree' via umbellulone and TRPA1 activates the trigeminovascular system. Brain (2011) 1.70
Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses. Proc Natl Acad Sci U S A (2008) 1.66
The transient receptor potential channel TRPA1: from gene to pathophysiology. Pflugers Arch (2012) 1.63
Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling. J Neurosci (2002) 1.61
Broad tuning of the human bitter taste receptor hTAS2R46 to various sesquiterpene lactones, clerodane and labdane diterpenoids, strychnine, and denatonium. J Agric Food Chem (2007) 1.59
N-oleoyldopamine, a novel endogenous capsaicin-like lipid that produces hyperalgesia. J Biol Chem (2003) 1.48
Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J Neurosci (2003) 1.47
Spatial learning deficit in transgenic mice that conditionally over-express GSK-3beta in the brain but do not form tau filaments. J Neurochem (2002) 1.42
Functional characterization of transient receptor potential channels in mouse urothelial cells. Am J Physiol Renal Physiol (2009) 1.39
Phosphorylation-dependent control of Pc2 SUMO E3 ligase activity by its substrate protein HIPK2. Mol Cell (2006) 1.37
Prenatal immune challenge disrupts sensorimotor gating in adult rats. Implications for the etiopathogenesis of schizophrenia. Neuropsychopharmacology (2002) 1.36
Development of the first potent and specific inhibitors of endocannabinoid biosynthesis. Biochim Biophys Acta (2006) 1.31
Hyperforin inhibits cancer invasion and metastasis. Cancer Res (2004) 1.27
Efficacy and safety of Meriva®, a curcumin-phosphatidylcholine complex, during extended administration in osteoarthritis patients. Altern Med Rev (2010) 1.26
An NMR spectroscopic method to identify and classify thiol-trapping agents: revival of Michael acceptors for drug discovery? Angew Chem Int Ed Engl (2011) 1.26
Bryostatin-1 synergizes with histone deacetylase inhibitors to reactivate HIV-1 from latency. Curr HIV Res (2010) 1.25
Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected. PLoS One (2011) 1.24
Activation of cannabinoid CB2 receptor negatively regulates IL-12p40 production in murine macrophages: role of IL-10 and ERK1/2 kinase signaling. Br J Pharmacol (2005) 1.20
Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation. J Nat Prod (2011) 1.19
Resveratrol potently reduces prostaglandin E2 production and free radical formation in lipopolysaccharide-activated primary rat microglia. J Neuroinflammation (2007) 1.17
Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia. Proc Natl Acad Sci U S A (2011) 1.16
The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients. AIDS (2012) 1.16
Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia. J Neurosci (2003) 1.14
Caffeic acid phenethyl ester inhibits T-cell activation by targeting both nuclear factor of activated T-cells and NF-kappaB transcription factors. J Pharmacol Exp Ther (2003) 1.14
Antibacterial cannabinoids from Cannabis sativa: a structure-activity study. J Nat Prod (2008) 1.13
Interleukin-1 regulates proliferation and differentiation of oligodendrocyte progenitor cells. Mol Cell Neurosci (2002) 1.12
Partial recessive IFN-γR1 deficiency: genetic, immunological and clinical features of 14 patients from 11 kindreds. Hum Mol Genet (2011) 1.10
The endocannabinoid system is modulated in response to spinal cord injury in rats. Neurobiol Dis (2008) 1.10
Chronic treatment with CP 55,940 during the peri-adolescent period differentially affects the behavioural responses of male and female rats in adulthood. Psychopharmacology (Berl) (2003) 1.07
Coumarins from Opopanax chironium. New dihydrofuranocoumarins and differential induction of apoptosis by imperatorin and heraclenin. J Nat Prod (2004) 1.06
Vanilloid receptor TRPV1 antagonists as the next generation of painkillers. Are we putting the cart before the horse? J Med Chem (2004) 1.06
Role of CB1 and CB2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide-induced nitric oxide release in astrocyte cultures. J Neurosci Res (2002) 1.06
A structure-activity relationship study on N-arachidonoyl-amino acids as possible endogenous inhibitors of fatty acid amide hydrolase. Biochem Biophys Res Commun (2004) 1.05
Noladin ether, a putative novel endocannabinoid: inactivation mechanisms and a sensitive method for its quantification in rat tissues. FEBS Lett (2002) 1.05
Activation of TRPA1 on dural afferents: a potential mechanism of headache pain. Pain (2012) 1.03
Tissue plasminogen activator prevents white matter damage following stroke. J Exp Med (2011) 1.03
Ischemic neuroprotection by TRPV1 receptor-induced hypothermia. J Cereb Blood Flow Metab (2012) 1.03
The human bitter taste receptor hTAS2R50 is activated by the two natural bitter terpenoids andrographolide and amarogentin. J Agric Food Chem (2009) 1.02
Neurobehavioral and immunological consequences of prenatal immune activation in rats. Influence of antipsychotics. Neuropsychopharmacology (2006) 1.02
In vivo estrogenic comparisons of Trifolium pratense (red clover) Humulus lupulus (hops), and the pure compounds isoxanthohumol and 8-prenylnaringenin. Chem Biol Interact (2008) 1.01
Effect of anandamide uptake inhibition in the production of nitric oxide and in the release of cytokines in astrocyte cultures. Glia (2005) 1.01
The synthetic cannabinoid WIN 55,212-2 increases COX-2 expression and PGE2 release in murine brain-derived endothelial cells following Theiler's virus infection. Biochem Pharmacol (2006) 1.00
Chronic exposure to morphine, cocaine or ethanol in rats produced different effects in brain cannabinoid CB(1) receptor binding and mRNA levels. Drug Alcohol Depend (2002) 1.00
Melatonin prevents oxidative stress and hepatocyte cell death induced by experimental cholestasis. Free Radic Res (2004) 1.00
Prospects for cannabinoid therapies in basal ganglia disorders. Br J Pharmacol (2011) 1.00
Effect of repeated systemic administration of selective inhibitors of endocannabinoid inactivation on rat brain endocannabinoid levels. Biochem Pharmacol (2005) 0.99
Anandamide enhances IL-10 production in activated microglia by targeting CB(2) receptors: roles of ERK1/2, JNK, and NF-kappaB. Glia (2010) 0.99
SJ23B, a jatrophane diterpene activates classical PKCs and displays strong activity against HIV in vitro. Biochem Pharmacol (2008) 0.99
Receptor agonism and antagonism of dietary bitter compounds. J Neurosci (2011) 0.99
Effects of the cyclooxygenase-2 inhibitor nimesulide on cerebral infarction and neurological deficits induced by permanent middle cerebral artery occlusion in the rat. J Neuroinflammation (2005) 0.99
Anandamide inhibits nuclear factor-kappaB activation through a cannabinoid receptor-independent pathway. Mol Pharmacol (2003) 0.98
Excitotoxicity in a chronic model of multiple sclerosis: Neuroprotective effects of cannabinoids through CB1 and CB2 receptor activation. Mol Cell Neurosci (2007) 0.98
Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide. Eur J Neurosci (2008) 0.98
Aggravated experimental autoimmune encephalomyelitis in IL-15 knockout mice. Exp Neurol (2010) 0.97
Immunosuppressive activity of capsaicinoids: capsiate derived from sweet peppers inhibits NF-kappaB activation and is a potent antiinflammatory compound in vivo. Eur J Immunol (2002) 0.97
In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake. Eur J Pharmacol (2004) 0.96
Spices: the savory and beneficial science of pungency. Rev Physiol Biochem Pharmacol (2013) 0.96
Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis. J Neurochem (2005) 0.96
Combination of biological screening in a cellular model of viral latency and virtual screening identifies novel compounds that reactivate HIV-1. J Virol (2012) 0.95
Antinociceptive, behavioural and neuroendocrine effects of CP 55,940 in young rats. Brain Res Dev Brain Res (2002) 0.94
Activation of latent HIV-1 expression by protein kinase C agonists. A novel therapeutic approach to eradicate HIV-1 reservoirs. Curr Drug Targets (2011) 0.93
Activation of the endocannabinoid system as therapeutic approach in a murine model of multiple sclerosis. FASEB J (2005) 0.93
Plant volatiles: production, function and pharmacology. Nat Prod Rep (2011) 0.93
Differential effects of phorbol-13-monoesters on human immunodeficiency virus reactivation. Biochem Pharmacol (2007) 0.93
4-Phenylcoumarins as HIV transcription inhibitors. Bioorg Med Chem Lett (2005) 0.92
In vitro antimalarial activity of hyperforin, a prenylated acylphloroglucinol. A structure-activity study. Bioorg Med Chem Lett (2007) 0.92
Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis. Neurobiol Dis (2005) 0.92
Anandamide inhibits IL-12p40 production by acting on the promoter repressor element GA-12: possible involvement of the COX-2 metabolite prostamide E(2). Biochem J (2008) 0.91
Antiproliferative effects on tumour cells and promotion of keratinocyte wound healing by different lichen compounds. Planta Med (2009) 0.91
Ligustilide: a novel TRPA1 modulator. Pflugers Arch (2011) 0.91
Human immunodeficiency virus type 1 Tat increases the expression of cleavage and polyadenylation specificity factor 73-kilodalton subunit modulating cellular and viral expression. J Virol (2004) 0.91
Calcium ionophoretic and apoptotic effects of ferutinin in the human Jurkat T-cell line. Biochem Pharmacol (2004) 0.91
Modulation of the transient receptor potential vanilloid channel TRPV4 by 4alpha-phorbol esters: a structure-activity study. J Med Chem (2009) 0.91
Jatrophane diterpenes as P-glycoprotein inhibitors. First insights of structure-activity relationships and discovery of a new, powerful lead. J Med Chem (2003) 0.90
A meroterpenoid NF-kappaB inhibitor and drimane sesquiterpenoids from Asafetida. J Nat Prod (2006) 0.90
Differential regulation of type I and type II interleukin-1 receptors in focal brain inflammation. Eur J Neurosci (2005) 0.90